Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-27T21:02:25.475Z Has data issue: false hasContentIssue false

Influnce of the beta-adrenergic agonist clenbuterol on plasma catecholamines and lymphocyte beta-receptors

Published online by Cambridge University Press:  28 April 2020

B. Bondy
Affiliation:
Psychiatric Hospital of University of Munich, Nuβbaumstraβe 7, 8000 München 2, FRG
M. Ackenheil
Affiliation:
Psychiatric Hospital of University of Munich, Nuβbaumstraβe 7, 8000 München 2, FRG
G. Laakmann
Affiliation:
Psychiatric Hospital of University of Munich, Nuβbaumstraβe 7, 8000 München 2, FRG
H.T. Munz
Affiliation:
Psychiatric Hospital of University of Munich, Nuβbaumstraβe 7, 8000 München 2, FRG
Get access

Summary

The influence of subchronic application of the β-adrenergic agonist clenbuterol on plasma norepinephrine (NE), epinephrine (E) and β-receptors on lymphocytes was investigated in 8 male, healthy volunteers. Treatment with clenbuterol (0.04 mg/day) for 6 days induced significant reduction of β-receptor specific binding in 7 of the 8 subjects with a mean decrease of 40% (p < 0.01) with no changes in affinity. Concomitantly an increase in the plasma NE concentration was observed (mean 50%, p < 0.01), but no significant overall alteration of E concentration. Our results suggest that β-adrenergic agonists exercise a similar effect on the peripheral adrenergic system and on the adrenergic system in the brain.

Résumé

Résumé

L’influence d’administrations subchroniques d’un agoniste bêta-adrénergique, le clenbutérol, sur les taux de noradrénaline (NE), d’adrénaline (E) plasmatiques et sur les bêta-récepteurs des lymphocytes a été etudiée chez 8 volontaires sains (hommes). Les catécholamines plasmatiques étaient déterminées par chromatographie liquide à haute pression couplée à un détecteur électro-chimique. Le ligand des bêta-récepteurs lymphocytaires était le bêta-bloquant 125-iodo-cyanopindolol (concentrations étagées de 3.4 à 150 pM). La liaison non spécifique était déterminée par 0.1 μM de propanolol. Le traitement par le clenbutérol(0.04 mg/jour) pendant 6 jours a induit une réduction significative de la liaison spécifique des bêta-récepteurs chez 7 des 8 sujets avec une diminution moyenne de 40 % (p < 0.01) sans changement d’affinité. Parallèlement, une augmentation de la concentration de noradrénaline (NE) plasmatique a été observée (moyenne 50 %, p < 0.01), mais pas de modification des concentrations d’adrénaline (E). Nos résultats suggèrent que les modifications du système noradrénergique et adrénergique induits par les agonistes bêta pourraient être similaires au niveau central et périphérique.

Type
Articels Courts/Brief Communications
Copyright
Copyright © European Psychiatric Association 1986

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References/Bibliographie

Ackenheil, M.Frohler, M.Goldig, G.Rall, G.Welter, D.- Catecholaminbestimmung im Blut und Liquor mit Hochdruck-flüssigkeitschromatographie und Elektrochemischem Detektor. Arzneimittelforsch 1982; 32 (II): 893.Google Scholar
Catt, K.Harwood, J.Aguilera, G.Dafau, M.- Hormonal regulation of peptide receptors and target cell responses. Nature 1980; 280:109116.CrossRefGoogle Scholar
Creese, I.Sibley, D.R.- Receptor adaptations to centrally acting drugs. Annu Rev Pharmacol Toxicol 1981; 21 : 357391.CrossRefGoogle ScholarPubMed
Galant, S.P.Durisetti, L.Underwood, S.Insel, P.A.- Decreased beta-adrenergic receptors on polymorphonuclear leukocytes after adrenergic therapy. N Engl J Med 1978; 299: 933936.CrossRefGoogle ScholarPubMed
Greenrace, J.K.Conolly, M.E.- Desensitization of the β-adrenoreceptor of lymphocytes from normal subjects and patients with phaeochromocytoma. Br J Clin Pharmacol 1978; 5:191197.Google Scholar
Hallberg, H.Almgren, D.Svensson, T.H.- Increased brain serotonergic and noradrenergic activity after repeated systemic administration of the beta-2-adrenoreceptor agonist salbutamol, a putative antidepressant drug. Psychopharmacology 1981; 73: 201204.CrossRefGoogle Scholar
Harden, T.K.Cotton, C.U.Waldo, G.L.Lutton, J.K.Perkins, J.P.- Catecholamine induced alterations in sedimentation behavior of membrane bound beta-adrenergic receptors. Science, 1980; Vol 210,10:441443.CrossRefGoogle Scholar
Harden, T.K.- Agonist induced desensitization of the β-adrenergic receptor-linked adanylate cyclase, Pharmacol Rev 1983; Vol 35, N° l : 532.Google ScholarPubMed
Hertel, C.Staehlen, M.- Reappearance of β-adrenergic receptors after isoproterenol treatment in intact C6 cells. J Cell Biol 1983; Vol 97:15381543.CrossRefGoogle ScholarPubMed
Hoyer, D.Reynolds, E.E.Molinoff, P.B.- Agonist induced changes in the properties of beta-adrenergic receptors on intact S49 lymphoma cells. Mol Pharmacol 1984; 25: 209218.Google ScholarPubMed
Lecrubier, Y.Puech, A.J.Jouvent, R.Simon, P.Widlocher, D.- A β-adrenergic stimulant (salbutamol) versus clomipramine in depression - a controlled study. Br J Psychiatry 1980; 136: 354358.CrossRefGoogle ScholarPubMed
Reisine, T.Heisler, S.- Desensitization of beta-adrenergic receptors linked to adrenocorticotropin secretion. J Pharmacol Exp Ther 1982; Vol 227, N° l : 107114.Google Scholar
Siever, L.J.Uhde, T.W.Potter, W.Z.Murphy, D.L.- Norepinephrine in the affective disorders: Receptor assessment strategies, In: Lake, C.R.Ziegler, M.G. eds.: The Catecholamines in Psychiatric and Neurologic Disorders, 235268, Butterworth Publishers, Boston, 1985.CrossRefGoogle Scholar
Sulser, F.- New perspectives on the mode of action of antidepressant drugs. Tips 1, 1979; 9294.Google Scholar
Submit a response

Comments

No Comments have been published for this article.